1-Boc-4-formylindoline

Catalog No.: 
ACLPGN608
CAS No.: 
1207194-48-6
Molecular Formula: 
C14H17NO3
Molecular Weight: 
247.29
1-Boc-4-formylindoline structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$62.00In stockIn stock
1g97%$162.00In stockInquiry
5g97%$638.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Boc-4-formylindoline
IUPAC Nametert-butyl 4-formylindoline-1-carboxylate
MDL No.MFCD14585005
Molecular FormulaC14H17NO3
Molecular Weight247.29
SMILESO=C(N1CCC2=C1C=CC=C2C=O)OC(C)(C)C
InChI KeyFEAIDQMPFVVRKA-UHFFFAOYSA-N
Synonym1-Boc-4-forMylindoline;tert-butyl 4-formylindoline-1-carboxylate;1H-Indole-1-carboxylic acid, 4-formyl-2,3-dihydro-, 1,1-dimethylethyl ester;tert-butyl 4-formyl-2,3-dihydro-1H-indole-1-carboxylate
CAS No.1207194-48-6
PubChem CID53393788

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACLPGN608 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCJVF207 route compound structure diagram
    ACCJVF207885272-46-8In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLPGN608 route product structure diagram
    ACLPGN6081207194-48-6In Stock
Inquiry

2. ACLPGN608 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACMVUD392 route compound structure diagram
    ACMVUD392143262-10-6
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLPGN608 route product structure diagram
    ACLPGN6081207194-48-6In Stock
Inquiry

3. ACLPGN608 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLPGN608 route product structure diagram
    ACLPGN6081207194-48-6In Stock
Inquiry

Comments (0)